NASDAQ:IBRX
ImmunityBio, Inc.
ImmunityBio, Inc.'s revenue grew 668.3% in fiscal 2025 to $113.3M while operating margin rose to −226.0%, its highest in 10 years. Free cash flow was −$308.8M, −272.6% of revenue, and the diluted share count rose 31.3%.Summary generated from ImmunityBio, Inc.'s SEC filings. Latest annual report filed Feb 23, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$113.3M
Revenue growth+668.3%
Revenue, 5-yr CAGR+184.8%
Gross margin99.3%
Operating margin−226.0%
Net margin−310.2%
ROICn/a
Return on equityn/a
Debt / equityn/a
Free cash flow−$308.8M
FCF margin−272.6%
Share count change+31.3%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 | 0 | 1 | 15 | 113 |
| Operating income | −330 | −351 | −362 | −344 | −256 |
| Net income | −347 | −417 | −583 | −414 | −351 |
| Free cash flow | −308 | −416 | −397 | −398 | −309 |
Recent filings
- 4Insider transaction report
Oct 6, 2026 - 4Insider transaction report
Oct 6, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Aug 4, 2026 - 8-KResults of operations and financial condition
Aug 4, 2026 - 8-KRegulation FD disclosure
Jul 30, 2026 - 8-KResults of a shareholder vote
Jun 10, 2026 - 8-KEntry into a material agreement
May 18, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
May 7, 2026